Division of Anatomical Science, Department of Functional Morphology, Nihon University School of Medicine, 30-1 Ohyaguchi-kami-machi, Itabashi-ku, Tokyo, 173-8610, Japan.
Center for Biological Safety and Research, National Institute of Health Sciences, Kawasaki, Japan.
Ann Hematol. 2020 Jul;99(7):1515-1523. doi: 10.1007/s00277-020-04095-2. Epub 2020 Jun 6.
Hemophagocytic lymphohistiocytosis (HLH) is a life-threatening systemic hyperinflammatory disorder. We found recently that repeated lipopolysaccharide (LPS) treatment induces HLH-like features in senescence-accelerated mice (SAMP1/TA-1) but not in senescence-resistant control mice (SAMR1). In this study, we analyzed the dynamics of hematopoiesis in this mouse model of HLH. When treated repeatedly with LPS, the numbers of myeloid progenitor cells (CFU-GM) and B-lymphoid progenitor cells (CFU-preB) in the bone marrow (BM) rapidly decreased after each treatment in both strains. The number of CFU-GM in SAMP1/TA-1 and SAMR1, and of CFU-preB in SAMR1, returned to pretreatment levels by 7 days after each treatment. However, the recovery in the number of CFU-preB in SAMP1/TA-1 was limited. In both strains, the BM expression of genes encoding positive regulators of myelopoiesis (granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), and interleukin (IL)-6), and negative regulators of B lymphopoiesis (tumor necrosis factor (TNF)-α) was increased. The expression of genes encoding positive regulators of B lymphopoiesis (stromal-cell derived factor (SDF)-1, IL-7, and stem cell factor (SCF)) was persistently decreased in SAMP1/TA-1 but not in SAMR1. Expression of the gene encoding p16 and the proportion of β-galactosidase-positive cells were increased in cultured stromal cells obtained from LPS-treated SAMP1/TA-1 but not in those from LPS-treated SAMR1. LPS treatment induced qualitative changes in stromal cells, which comprise the microenvironment supporting appropriate hematopoiesis, in SAMP1/TA-1; these stromal cell changes are inferred to disrupt the dynamics of hematopoiesis. Thus, hematopoietic tissue is one of the organs that suffer life-threatening damage in HLH.
噬血细胞性淋巴组织细胞增生症(HLH)是一种危及生命的全身性炎症反应亢进性疾病。我们最近发现,重复给予脂多糖(LPS)可诱导衰老加速小鼠(SAMP1/TA-1)出现 HLH 样特征,但不诱导衰老抵抗对照小鼠(SAMR1)出现此类特征。在这项研究中,我们分析了该 HLH 小鼠模型中造血的动态变化。当用 LPS 重复处理时,两种品系的骨髓(BM)中髓系祖细胞(CFU-GM)和 B 淋巴细胞祖细胞(CFU-preB)的数量在每次处理后都迅速减少。在 SAMP1/TA-1 和 SAMR1 中 CFU-GM 的数量以及在 SAMR1 中 CFU-preB 的数量在每次处理后 7 天内恢复到预处理水平。然而,SAMP1/TA-1 中 CFU-preB 数量的恢复是有限的。在两种品系中,BM 中编码髓系生成正调控因子(粒细胞集落刺激因子(G-CSF)、粒细胞巨噬细胞集落刺激因子(GM-CSF)和白细胞介素(IL)-6)和 B 淋巴细胞生成负调控因子(肿瘤坏死因子(TNF)-α)的基因表达增加。编码 B 淋巴细胞生成正调控因子(基质细胞衍生因子(SDF)-1、IL-7 和干细胞因子(SCF))的基因表达在 SAMP1/TA-1 中持续降低,但在 SAMR1 中不降低。来自 LPS 处理的 SAMP1/TA-1 的基质细胞中,编码 p16 的基因表达和β-半乳糖苷酶阳性细胞的比例增加,但来自 LPS 处理的 SAMR1 的基质细胞中不增加。LPS 处理诱导 SAMP1/TA-1 中的基质细胞发生定性变化,这些细胞构成了支持适当造血的微环境;这些基质细胞的变化被推断会破坏造血的动态变化。因此,造血组织是 HLH 中遭受危及生命损害的器官之一。